GlassScriptPhysician profile
Sepideh Gholami
NPI 1982865606
$31,592.41
in general payments reported to CMS, 2019-2025
16 companies · $12K in 2025
The $12K reported for 2025 was more than what 94% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $855 · 2020: $52.68 · 2021: $12K · 2022: $476 · 2023: $4,656 · 2024: $2,297 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,306 · Consulting Fee: $4,965 · Travel and Lodging: $2,825 · Food and Beverage: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,306.25 |
| Consulting Fee | $4,965.00 |
| Travel and Lodging | $2,825.45 |
| Food and Beverage | $2,475.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $9,523.18 | 2025 | General - Interventional Oncology, Therasphere Y90 Glass Microspheres 10 Gbq |
| Helsinn Therapeutics (U.S.), INC. | $8,542.55 | 2021-2022 | |
| Intuitive Surgical, INC. | $4,153.78 | 2019-2024 | |
| Genentech USA, INC. | $4,114.46 | 2023 | Tecentriq |
| Delcath Systems | $1,800.00 | 2024 | Hepzato Kit |
| Histosonics, INC. | $1,337.64 | 2025 | |
| Dilon Technologies, INC. | $992.02 | 2024-2025 | Hemoblast Bellows |
| Intera Oncology, INC | $672.65 | 2022-2024 | Intera 3000 Implantable Pump, Intera |
| Trisalus Life Sciences, INC. | $123.01 | 2023 | Trinav Infusion System |
| Conmed Corporation | $121.22 | 2021 | |
| Genentech, INC. | $69.96 | 2023 | |
| Medtronic USA, INC. | $52.68 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $50.68 | 2019 | |
| Solventum Corporation | $38.58 | 2025 | V.A.C. Dermatac, Prevena, Abthera Advance |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sepideh Gholami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.